Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 24, 2008, Pages 6486-6489

  Jones, Clifford D ^a   Andrews, David M ^a   Barker, Andrew J ^a   Blades, Kevin ^a   Byth, Kate F ^a   Finlay, M Raymond V ^a   Geh, Catherine ^a   Green, Clive P ^a   Johannsen, Marie ^a   Walker, Mike ^a   Weir, Hazel M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Cancer; CDK; Cell cycle; Cyclin dependent kinase; Imidazole amide; Kinase; Kinase inhibitor

Indexed keywords

CYCLIN DEPENDENT KINASE 2 INHIBITOR; METHYLAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; FEMALE; IC 50; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, NUDE; PYRIMIDINES; RATS; RATS, WISTAR;

EID: 56249112601     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.075     Document Type: Article

References (10)

1. Sharma P.S., Sharma R., and Tyagi R. Curr. Cancer Drug Targets 8 (2008) 53
2. Byrd J.C., Lin T.S., Dalton J.T., Wu D., Phelps M.A., Fischer B., Moran M., Blum K.A., Rovin B., Brooker-McEldowney M., Broering S., Schaaf L.J., Johnson A.J., Lucas D.M., Heerema N.A., Lozanski G., Young D.C., Suarez J.-R., Colevas A.D., and Grever M.R. Blood 15 (2007) 399
3. Anderson M., Beattie J.F., Breault G.A., Breed J., Byth K.F., Culshaw J.D., Ellston R.P.A., Green S., Minshull C.A., Norman R.A., Pauptit R.A., Stanway J., Thomas A.P., and Jewsbury P.J. Bioorg. Med. Chem. Lett. 13 (2003) 3021
4. Byth K.F., Culshaw J.D., Green S., Oakes S.E., and Thomas A.P. Bioorg. Med. Chem. Lett 14 (2004) 2245
5. Byth K.F., Cooper N., Culshaw J.D., Heaton D.W., Oakes S.E., Minshull C.A., Norman R.A., Pauptit R.A., Tucker J.A., Breed J., Pannifer A., Rowsell S., Stanway J.J., Valentine A.L., and Thomas A.P. Bioorg. Med. Chem. Lett. 14 (2004) 2249
6. Anderson M., Andrews D.M., Barker A.J., Brassington C.A., Breed J., Byth K.F., Culshaw J.D., Finlay M.R.V., Fisher E., Gingell H.H.J., Green C.P., Heaton D.W., Nash I.A., Newcombe N.J., Oakes S.E., Pauptit R.A., Roberts A., Stanway J.J., Thomas A.P., Tucker J.A., and Weir H.M. Bioorg. Med. Chem. Lett. 18 (2008) 5487
7. Finlay M.R.V., Acton D.G., Andrews D.M., Barker A.J., Dennis M., Fisher E., Graham M.A., Green C.P., Heaton D.W., Karoutchi G., Loddick S.A., Morgentin R., Roberts A., Tucker J.A., and Weir H.M. Bioorg. Med. Chem. Lett. 18 (2008) 4442
8. Schroeder K., Neagle B., Trezise DJ., and Worley J. J. Biomol. Screen. 8 (2003) 50
9. Against Cyp isoforms: 3A4, 2D6, 2C9, 2C19 and 1A2.
10. Andrews, D.; Finlay, M. R.; Green, C.; Jones, C. PCT Int. Application WO2006-064251.